Pulmonary Disease in Mesquite, TX
3 verified pulmonary disease doctors in Mesquite.
Pulmonologists diagnose and treat diseases of the lungs and respiratory system, such as asthma, COPD, and sleep apnea.
NPPES tenure ≠ clinical experience. "Years on NPPES" is time since the physician first registered a National Provider Identifier, not time practicing medicine. Verify current license status with the state medical board.
Dr. Yousef Kayyas, MD
Pulmonary Disease
CMS Open Payments· $16.20 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$16.20
Total received
1
Transactions
1
Paying companies
Top paying companies
Among the 13,317 pulmonary disease doctors we've analyzed, about 54% received any industry payment (median $474 among those who did). This doctor's total is on the lower end — around the 47th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US pulmonary disease doctors.
Payments to Yousef Kayyas do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Samer Nachawati, DO
Pulmonary Disease
CMS Open Payments· $817,102 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$817,102
Total received
36
Transactions
8
Paying companies
Top paying companies
Among the 13,317 pulmonary disease doctors we've analyzed, about 54% received any industry payment (median $474 among those who did). This doctor's total is higher than 100% of that group — among the highest recipients.
Benchmark reflects doctors we've analyzed, not all US pulmonary disease doctors.
Payments to Samer Nachawati do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Adeel Shibli, MD
Pulmonary Disease
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.